Table 2 Ultrastaging of sentinel lymph node using H&E, serial sectioning and IHC in patients with cervical cancer
Study | Year | Method of analysis | Nb of patients | FIGO stage | Macrometastatic SLN (%) | Micrometastatic SLN (%) |
|---|---|---|---|---|---|---|
Lantzsch | 2001 | H&E +SS+IHC | 14 | IB1 | 1 (7.1) | 0 |
Plante | 2003 | H&E +SS+IHC | 70 | IA-IIA | 8 (13.1) | 3 (37.5) |
Dargent | 2003 | H&E +SS+IHC | 70 | IA1-IIB | 19 (30.2) | 9 (47.4) |
Hubalewska | 2003 | H&E +SS+IHC | 37 | I-IIA | 5 (13.5) | na |
Pijpers | 2004 | H&E +SS+IHC | 34 | early | 12 (36.3) | 4 (33) |
Silva | 2005 | H&E +SS+IHC | 56 | IA2-IIA | 17 (32.7) | 3 (17.6) |
Rob | 2005 | H&E +SS+IHC | 183 | IA2-IB2 | 35 (21.9) | na |
Angioli | 2005 | H&E +SS+IHC | 37 | IB1 | 6 (23) | 0 |
Di Stefano | 2005 | H&E +SS+IHC | 50 | IA2-IIA | 9 (20) | 2 (22.2) |
Frumovitz | 2006 | H&E +SS+IHC | 50 | IA2-IB1 | 9 (18.8) | na |
Wang | 2006 | H&E +SS+IHC+CK19PCR | 46 | early | 18 (39) | 7 (38.9) |
Yuan | 2007 | H&E +SS+IHC | 81 | IB1-IIA | 17(20.9) | 4 (23.5) |
Coutant | 2007 | H&E +SS+IHC+HPV DNA | 59 | IA-II | 15 (25.4) | 3 (20) |
Lee | 2007 | H&E +HPV DNA | 57 | IB-IIA | 11 (19.3) | na |
Hauspy | 2007 | H&E +SS+IHC | 39 | IA1-IIA | 2 (5.2) | na |
Bats | 2007 | H&E +SS+IHC | 25 | IA2-IA1 | 3 (12) | 1 (33) |
Total | Â | Â | 908 | Â | 187 (20.6) | 36 (19.2) |